Clinical bottom line
Artificial intelligence (AI) shows promise as a tool to predict kidney stone recurrence by integrating clinical, biochemical, and imaging data. Early studies suggest AI models may improve risk stratification beyond traditional methods, potentially guiding personalized prevention and follow-up strategies. However, current evidence is preliminary, and further validation in diverse populations is needed before routine clinical implementation (Checcucci et al., 2020; Shpitzer et al., 2025).
What the evidence shows
Checcucci et al. (2020) review current clinical applications of AI and neural networks in urology, highlighting their potential to analyze complex datasets for predicting outcomes including stone recurrence. AI algorithms can incorporate multiple variables such as patient demographics, stone composition, metabolic profiles, and imaging features to generate individualized risk assessments.
Shpitzer et al. (2025) emphasize the role of stone composition in recurrence risk stratification and discuss how AI models integrating compositional data with clinical parameters may enhance prediction accuracy. Their work suggests that AI-driven risk models could identify patients at high risk for repeat stone surgery, enabling targeted interventions.
Although not specific to kidney stones, Uchino et al. (2021, 2022) demonstrate AI’s capability in predicting kidney function and acute kidney injury by combining patient records and imaging, supporting the feasibility of similar approaches in stone disease.
Geng et al. (2026) illustrate AI model development for predicting spontaneous passage of common bile duct stones using endoscopic ultrasonography data, providing a conceptual framework applicable to urolithiasis.
Caveats and uncertainty
Most AI studies in kidney stone recurrence are retrospective and involve relatively small cohorts, limiting generalizability.
Heterogeneity in data sources, imaging protocols, and outcome definitions complicates model development and validation.
The biological mechanisms underlying stone recurrence are multifactorial and incompletely captured by current datasets.
Integration of AI tools into clinical workflows requires user-friendly interfaces and clinician training.
Regulatory approval and ethical considerations around AI decision support remain evolving.
How this may change practice
AI-based predictive models could enable personalized risk stratification for kidney stone recurrence, informing tailored surveillance intervals and preventive measures.
Incorporation of stone composition and metabolic data into AI algorithms may refine patient counseling and management plans.
Radiologists and urologists may collaborate with data scientists to develop and validate clinically relevant AI tools.
Future clinical decision support systems may integrate AI predictions to optimize resource allocation and improve patient outcomes.
Ongoing research and prospective validation are essential before widespread adoption.